Celcuity (NASDAQ:CELC) Shares Gap Down – Should You Sell?

Celcuity, Inc. (NASDAQ:CELC) shares gapped down before the market opened on Wednesday . The stock had previously closed at $111.05, but opened at $94.81. Celcuity shares last traded at $95.9020, with a volume of 1,773,091 shares trading hands.

Wall Street Analysts Forecast Growth

CELC has been the subject of a number of research analyst reports. Craig Hallum decreased their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. HC Wainwright upped their price objective on Celcuity from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday. Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Citizens Jmp boosted their target price on shares of Celcuity from $160.00 to $177.00 and gave the company a “market outperform” rating in a research note on Wednesday. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Stock Down 17.9%

The stock has a market cap of $4.45 billion, a PE ratio of -23.59 and a beta of 0.16. The business has a fifty day moving average of $110.83 and a 200-day moving average of $111.13. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. Equities research analysts anticipate that Celcuity, Inc. will post -3.69 earnings per share for the current year.

Insider Transactions at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares in the company, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.

Institutional Trading of Celcuity

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. lifted its holdings in Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares during the period. Ogorek Anthony Joseph NY ADV grew its stake in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the period. US Bancorp DE increased its holdings in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Celcuity by 1.4% during the 4th quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock valued at $1,295,000 after purchasing an additional 183 shares in the last quarter. Finally, Aristides Capital LLC lifted its stake in shares of Celcuity by 2.0% in the 4th quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock valued at $1,526,000 after purchasing an additional 303 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.